Please use this identifier to cite or link to this item:
Title: Antibody-Drug Conjugates for Cancer Therapy.
Austin Authors: Parslow, Adam C;Parakh, Sagun ;Lee, Fook-Thean;Gan, Hui K ;Scott, Andrew M 
Affiliation: Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, University of Melbourne, Melbourne 3010, Australia
Issue Date: 11-Jul-2016 2016-07-11
Publication information: Biomedicines 2016; 4(3): E14
Abstract: Antibody-drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance.
DOI: 10.3390/biomedicines4030014
ORCID: 0000-0003-3891-2489
PubMed URL: 28536381
ISSN: 2227-9059
Type: Journal Article
Subjects: ADC
antibody–drug conjugate
monoclonal antibodies
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.